Recent Releases

Proposed Fundraise of £28.9m and Cancellation

16 January 2024

Business Update

26 October 2023

Interim Results for the financial year 2023/2024

Final results for the year ended 31 January 2023

07 February 2023

Filing of four new patent applications

30 September 2022

Successful completion of £13.5 million fundraise

30 September 2022

Interim Results for the financial year 2022/2023

Filing of eight patent applications on proprietary GalNAc-siRNA technology and target related...

Result of Annual General Meeting

Director Dealing and Issue of Equity

Filter by:

Proposed Fundraise of £28.9m and Cancellation

16 January 2024

Business Update

26 October 2023

Interim Results for the financial year 2023/2024

Final results for the year ended 31 January 2023

07 February 2023

Filing of four new patent applications

30 September 2022

Successful completion of £13.5 million fundraise

30 September 2022

Interim Results for the financial year 2022/2023

Filing of eight patent applications on proprietary GalNAc-siRNA technology and target related...

Result of Annual General Meeting

Director Dealing and Issue of Equity

Notice of Annual General Meeting and Posting of Annual Report and Accounts

Final results for the year ended 31 January 2022

Key Milestone Achieved and Significant Progress on Galapagos Collaboration

Immuno-Oncology Research Collaboration with iTeos Therapeutics

22 November 2021

Senior Management Update

26 October 2021

Interim results for six months ended 31 July 2021

26 October 2021

RNAi Platform Characterisation Results

20 October 2021

Investor Presentation

11 October 2021

Notice of Interim Results

11 October 2021

Patent Filing Applications

24 September 2021

Commencement of trading on the OTCQX Best Market

Further milestone in Galapagos collaboration

Senior Management Appointment and Options Grant

Results of conditional Fundraise to raise £22.5 million

Proposed Fundraise in excess of £20 million

Final Results for the Year Ended 31 January 2021

Notification of Full Year Results Date

ETX to receive two payments from Galapagos

Appointment of Chief Financial Officer

Change of Adviser

16 February 2021

e-therapeutics to present at Shares Investor Evening

01 February 2021

RNA Therapeutics Platform

08 December 2020

COVID-19 Project Update

12 October 2020

Appointment of Ali Mortazavi as CEO

12 October 2020

Interim Results for six months ended 31 July 2020

05 October 2020

Notice of Interim Results

28 September 2020

Expansion of Scientific Advisory Board

Exercise of Broker Option and Total Fundraise

Exercise of Broker Option

Result of Retail Offer

Fundraise of up to £12.4 million

Collaboration with Galapagos

Expansion into RNAi and creation of SAB

COVID-19 update: experimental testing initiated with WuXi AppTec

e-therapeutics to present at Shares Investor Evening

Appointment of Chief Business Officer

Notice of Annual General Meeting and Annual Report

Anti-viral drug discovery initiative

Results for the year ended 31 January 2020

Notification of Full Year Results Date

11 February 2020

Board Changes and Placing

07 October 2019

Half-year Report

e-therapeutics to work with top pharma company

Extends Research Collaboration with Novo Nordisk

Full Year Results

20 February 2019

Notification of Full Year Results Date

10 December 2018

Research Collaboration Agreement with Novo Nordisk

06 December 2018

E-therapeutics and C4X Collaboration

29 November 2018

Drug Discovery Innovation Programme Presentation

12 November 2018

e-therapeutics to present at BioCentury Summit

04 October 2018

Interim Results for six months ended 31 July 2018

17 September 2018

Notice of Interim Results

Collaboration with C4X Discovery Holdings PLC

Full Year Results

Notification of Full Year Results Date

15 January 2018

E-Therapeutics enters two AI collaborations

01 November 2017

Appointment of Director

26 September 2017

Interim Results for the 6 Months Ended 31 July 2017

05 September 2017

Notice of Results

Edison issues update on e-Therapeutics (ETX)

Outcome of Strategic Review and Future Plans

Notification of Full Year Results Date

New CEO Commences at e-Therapeutics

16 February 2017

Directorate Change

09 January 2017

Appointment of CEO